A new study from UC Davis Health could help to increase the supply of donor kidneys. Researchers have found that transplant patients who receive kidneys infected with the parasite toxoplasma… read more.
The biologics license application (BLA) seeking the approval of tabelecleucel (tab-cel) monotherapy for the treatment of adult and pediatric patients who are at least 2 years of age… read more.
A new treatment approach using an older drug may enable more patients with high-risk blood cancers to receive transplanted stem cells from unrelated, partially matched donors, according to… read more.
Azurity Pharmaceuticals, a pharmaceutical company focused on developing innovative dose forms and formulations of products to serve the needs of overlooked patients, announced that the FDA has approved… read more.
Merck Inc. known as MSD outside of the United States and Canada, announced that Health Canada has approved a new indication for Prevymis (letermovir) for the prophylaxis of… read more.
While debating the pros and cons of robotically assisted lung transplantation, Albert Jauregui, MD, PhD told attendees at the Annual Meeting and Scientific Sessions of the International Society… read more.
A collaborative study between a bariatric and transplant surgery team has introduced new hope for patients suffering from end-stage renal disease (ESRD) who are also struggling with obesity…. read more.
The European Medicines Agency, the EU drug watchdog, has approved the first medicine using CRISPR/Cas9, a novel gene-editing technology. Casgevy (exagamglogene autotemcel) is indicated for the treatment of… read more.
Atara Biotherapeutics, Inc. announced the closing of the expanded global partnership with Pierre Fabre Laboratories for tabelecleucel (tab-cel or Ebvallo). Building on the earlier partnership announced in October… read more.
A new study has found there is significant scope to increase the number of eye donations from patients cared for in hospice and palliative care settings – donations… read more.
Hansa Biopharma announced results from an extended pooled analysis using data from the 17-HMedIdeS-14 study, an international long-term follow-up study of patients who have received a kidney transplant… read more.
Hansa Biopharma announced randomization for the US ConfIdeS trial is expected to conclude in mid-2024. The ConfIdeS trial is an open-label, controlled, randomized Phase III trial evaluating 12-month… read more.
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
